Drugs / MVA Smallpox Vaccine
MVA Smallpox Vaccine
also known as
IMVAMUNE · Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine · MVA BN(R) · Vaccinia Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00879762 | May 2009 → Mar 2011 | smallpox | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02743455 Comparator | Jul 2016 → Mar 2018 | yellow fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA Smallpox Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02743455 ↗ |
| Known as | IMVAMUNE | “The purpose of this research is to compare the ability of a new investigational smallpox vaccine called IMVAMUNE® to produce a strong immune response against smallpox disease” NCT00879762 ↗ |
| Known as | Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine | “Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine (MVA BN(R)) is a purified live vaccine will be used as an active comparator.” NCT02743455 ↗ |
| Known as | MVA BN(R) | “Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine (MVA BN(R)) is a purified live vaccine will be used as an active comparator.” NCT02743455 ↗ |
| Known as | Vaccinia Vaccine | “IMVAMUNE® Vaccinia Vaccine, undiluted, delivered by subcutaneous route” NCT00879762 ↗ |
| Modality | Vaccine | “new investigational smallpox vaccine called IMVAMUNE®” NCT00879762 ↗ |
| Route | Subcutaneous | “delivered by subcutaneous route” NCT00879762 ↗ |